Furthermore, a SPATR-based vaccine generated humoral and mixed Th1/Th2 type cellular immune responses inducing lymphocyte proliferation and cytokine (IFN-γ, IL-2, IL-4 and IL-10) secretion, showing that SPATR may be a promising vaccine candidate against toxoplasmosis [135]. This evidence concerns the gene IFNG and toxoplasmosis.